Study S001924

Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07642635
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1; PHASE2
Masking: QUADRUPLE
Status: NOT_YET_RECRUITING
Enrollment: 30
Start: 2026-09-01
Primary completion: 2030-09
Lead sponsor: Vanderbilt University Medical Center
Conditions: Duchenne Muscular Dystrophy (DMD)
Interventions: DRUG:Semaglutide (Rybelsus®); OTHER:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Muscle Volume Index (MVI) [Week 0 (baseline), week 24 (end of RCT), week 64 (end of study)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.